C-reactive protein: Difference between revisions
imported>Howard C. Berkowitz m (→Diagnostic use) |
imported>Howard C. Berkowitz mNo edit summary |
||
| Line 5: | Line 5: | ||
==Diagnostic use== | ==Diagnostic use== | ||
Along with the [[erythrocyte sedimentation rate]], when laboratory results are elevated, the clinician has warning an an acute inflammatory disorder exists.<ref name=Husain2002>{{citation | Along with the [[erythrocyte sedimentation rate]], when laboratory results are elevated, the clinician has warning an an acute inflammatory disorder exists.<ref name=Husain2002>{{citation | ||
| | | volume=15 | ||
| date =Spring 2002 | | date =Spring 2002 | ||
| | | pages=13-16 | ||
| title = C-Reactive Protein and Erythrocyte Sedimentation Rate in Orthopaedics | | title = C-Reactive Protein and Erythrocyte Sedimentation Rate in Orthopaedics | ||
| author = Husain TM, Kim DH | | author = Husain TM, Kim DH | ||
| Line 22: | Line 22: | ||
| title = Giant cell arteritis | | title = Giant cell arteritis | ||
| publisher = Merck Manual for Healthcare Professionals | | publisher = Merck Manual for Healthcare Professionals | ||
}}</ref> or [[ | }}</ref> or [[microscopic polyangiitis]]<ref name=MerckHP-MicroPuly>{{citation | ||
| title = Microscoping polyangiitis | | title = Microscoping polyangiitis | ||
| publisher = Merck Manual for Healthcare Professionals | | publisher = Merck Manual for Healthcare Professionals | ||
| Line 29: | Line 29: | ||
The presence, in high-sensitivity CRP analysis, shows a predisposition to [[atheroscerosis|atherosclerotic blood vessel disease]].<ref name=Flores-Alfaro>{{citation | The presence, in high-sensitivity CRP analysis, shows a predisposition to [[atheroscerosis|atherosclerotic blood vessel disease]].<ref name=Flores-Alfaro>{{citation | ||
| journal =Circ J. | | journal =Circ J. | ||
| date = July | | date = July 2008 | ||
|volume = 72(7) | |volume = 72(7) | ||
|pages = 1170-4. | |pages = 1170-4. | ||
|title=Cardiovascular risk evaluated by C-reactive protein levels in diabetic and obese Mexican subjects. | |title=Cardiovascular risk evaluated by C-reactive protein levels in diabetic and obese Mexican subjects. | ||
| | | author = Flores-Alfaro E, Parra-Rojas I, Salgado-Bernabé AB, Chávez-Maldonado JP,Salazar-Martinez E. | ||
| url = http://www.ncbi.nlm.nih.gov/pubmed/18577830 | | url = http://www.ncbi.nlm.nih.gov/pubmed/18577830 | ||
| PMID =18577830}} | | PMID =18577830}}</ref> | ||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
Revision as of 21:46, 18 October 2008
Template:TOC-right C-reactive protein (CRP) is one of the circulating blood proteins that help the host defense system begin immune defense by phagocytosis performed my macrophage. Its opsonization of target cells is much less precise than from immunoglobulin generated by B-lympocytes for T8 lymphocytes. When activated, it binds, with the antigen, to a surface receptor on macrophages and opsonize the threatening cells.
Diagnostic use
Along with the erythrocyte sedimentation rate, when laboratory results are elevated, the clinician has warning an an acute inflammatory disorder exists.[1]
Elevation above the patient's baseline assist in assessing lipid measurements in apparently healthy people. They are also appear predictive of peripheral vacular disease, supporting the theory that chronic inflammation precedes atherosclerosis. There is early evidence exists that risk factor modification, particularly the use of aspirin and the Hydroxymethylglutaryl-coenzyme A reductase inhibitors (i.e., statins, may reduce plaque inflammation.[2] CRP is a better predictor inflammatory disease than the erythrocyte sedimentation rate in a vasculitis such as giant cell arteritis, also called temporal arteritis; cranial arteritis; or Horton's disease [3] or microscopic polyangiitis[4]
The presence, in high-sensitivity CRP analysis, shows a predisposition to atherosclerotic blood vessel disease.[5]
References
- ↑ Husain TM, Kim DH (Spring 2002), "C-Reactive Protein and Erythrocyte Sedimentation Rate in Orthopaedics", University of Pennsylvania Orthopedic Journal 15: 13-16
- ↑ F Brian Boudi, Chowdhury H Ahsan, James L Orford, Andrew P Selwyn (Aug 10, 2006), "Atherosclerosis", eMedicine
- ↑ Giant cell arteritis, Merck Manual for Healthcare Professionals
- ↑ Microscoping polyangiitis, Merck Manual for Healthcare Professionals
- ↑ Flores-Alfaro E, Parra-Rojas I, Salgado-Bernabé AB, Chávez-Maldonado JP,Salazar-Martinez E. (July 2008), "Cardiovascular risk evaluated by C-reactive protein levels in diabetic and obese Mexican subjects.", Circ J. 72(7): 1170-4.